CYP2C19 c. 681G >A Is not in Complete Linkage Disequilibrium With c.332‐ 23A >G: Implications for Pharmacogenetic Testing
Clinical and Translational Science · 2026-08 · 19 (8)
DOI: 10.1111/cts.70684 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, online erschienen am 31.07.2026. Verfasst von Amy J Turner und 8 weiteren Autor:innen. Beteiligte Einrichtung: RPRD Diagnostics LLC, Milwaukee, Wisconsin, USA. Hauptthemen laut MEDLINE: Cytochrome P-450 CYP2C19, Pharmacogenomic Testing, Linkage Disequilibrium, Pharmacogenomic Variants. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
CYP2C19 plays an important role in the metabolism of many medications, including the antiplatelet agent clopidogrel, the antifungal agent voriconazole, selective serotonin reuptake inhibitors, select tricyclic antidepressants, and proton pump inhibitors. The Clinical Pharmacogenetics Implementation Consortium has published several guidelines emphasizing the importance of CYP2C19 genotype‐guided therapy to optimize patient outcomes. Formerly, the no function CYP2C19*2 allele was defined by three variants, c.332‐23A>G (splice defect), c.681G>A (splice defect), and c.991A>G (p.I331V). The discovery of two new haplotypes, one containing only a single variant, c.681G>A, and another with only c.681G>A and c.991A>G, challenged the assumption that c.681G>A always occurred together with c.332‐23A>G. PharmVar designated these new haplotypes as CYP2C19*2.018 and *2.019 , respectively, prompting the revision of the CYP2C19*2 core allele to be defined solely by the single variant, c.681G>A. Although the variants interrogated to identify CYP2C19*2 and *35 remain the same, subjects who are heterozygous for c.332‐23A>G (present on most CYP2C19*2 and all *35 alleles) and c.681G>A (present on all CYP2C19*2 alleles) may, in rare cases, have a CYP2C19*2/*35 poor metabolizer diplotype (variants in trans ) and not a CYP2C19*1/*2 intermediate metabolizer diplotype (variants in cis ). CYP2C19*2 alleles with c.681G>A, but not c.332‐23A>G, were found in subjects across diverse populations and are estimated to have a frequency around 0.03%. These findings, along with the revision of the CYP2C19*2 core allele definition, have implications for variant testing, test interpretation and reporting.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- RPRD Diagnostics LLC, Milwaukee, Wisconsin, USA.
- Division of Clinical Pharmacology, Toxicology & Therapeutic Innovation, Children's Mercy, Kansas City, Missouri, USA.
- Department of Pharmacy and Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
- Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, USA.
- Department of Pharmacy and Therapeutics, University of Pittsburgh School of Pharmacy, Pittsburgh, Pennsylvania, USA.
- School of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA.
ORCID-Profile: Amy J Turner, Erin C Boone, Cyrine E Haidar, Wenjian Yang, Ashley D Derezinski, Andrew Haddad, Philip E Empey, Ulrich Broeckel, Andrea Gaedigk
Förderung
- NIH HHS
- National Institutes of Health
Zitieren
APA
Turner, A. J., Boone, E. C., Haidar, C. E., Yang, W., Derezinski, A. D., Haddad, A., Empey, P. E., Broeckel, U., & Gaedigk, A. (2026). CYP2C19 c. 681G >A Is not in Complete Linkage Disequilibrium With c.332‐ 23A >G: Implications for Pharmacogenetic Testing. Clinical and Translational Science, 19(8). https://doi.org/10.1111/cts.70684
Vancouver
Turner AJ, Boone EC, Haidar CE, Yang W, Derezinski AD, Haddad A, et al. CYP2C19 c. 681G >A Is not in Complete Linkage Disequilibrium With c.332‐ 23A >G: Implications for Pharmacogenetic Testing. Clinical and Translational Science. 2026;19(8). doi:10.1111/cts.70684
BibTeX
@article{Turner2026,
author = {Turner, Amy J and Boone, Erin C and Haidar, Cyrine E and Yang, Wenjian and Derezinski, Ashley D and Haddad, Andrew and Empey, Philip E and Broeckel, Ulrich and Gaedigk, Andrea},
title = {CYP2C19 c. 681G >A Is not in Complete Linkage Disequilibrium With c.332‐ 23A >G: Implications for Pharmacogenetic Testing},
journal = {Clinical and Translational Science},
year = {2026},
volume = {19},
number = {8},
doi = {10.1111/cts.70684}
}
EUVIMED